AURORA: A New Dawn
Author Information
Author(s): Papanicolaou Genovefa A, Avery Robin K, Cordonnier Catherine, Duarte Rafael F, Haider Shariq, Maertens Johan, Peggs Karl S, Solano Carlos, Young Jo-Anne H, Fournier Martha, Murray Rose Ann, Wu Jingyang, Bo Tien, Winston Drew J
Primary Institution: Takeda Development Center Americas, Inc
Hypothesis
AURORA was the first randomized, double-blind study to compare 2 oral antiviral agents with a primary end point of cytomegalovirus (CMV) clearance.
Conclusion
AURORA confirmed the anti-CMV activity of maribavir with less neutropenia compared with valganciclovir for CMV infection after hematopoietic stem cell transplant.
Supporting Evidence
- Comparable viremia clearance was achieved during 8 weeks of treatment (maribavir: 83%; valganciclovir: 86%).
- Patients had fewer treatment-emergent adverse events (TEAEs), hospitalizations, and TEAE-related discontinuations with maribavir than with valganciclovir.
- More recurrent CMV infections occurred after the 8-week treatment period with valganciclovir (23% vs 19%).
- Maribavir's efficacy and safety profile enables its use among patients at risk of intolerances.
Takeaway
This study looked at two medicines to help people with a virus called CMV after a transplant. One medicine worked better and caused fewer side effects.
Methodology
Randomized, double-blind study comparing maribavir and valganciclovir.
Potential Biases
Potential bias due to the study design and strict entry criteria.
Limitations
The study had an 8-week treatment period and included high-risk patients with a lower viral load than originally planned.
Participant Demographics
18% of the study population were high-risk patients with a viral load >455 IU/mL.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website